Vanda Pharmaceuticals

VNDA · Nasdaq · United States

Share price · VNDA

$3.75-1.69 (-31.07%) 3M

close as of 2026-11-18 · 24h delayed · vol 949K (0.8x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when VNDA's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 3 Nov 2026-3.4%
  2. 30 Oct 2026-6.4%
  3. 12 Aug 2026+5.3%
  4. 5 Aug 2026-4.5%
  5. 20 Mar 2026-16.9%
  6. 23 Feb 2026+41.5%
  7. 12 Feb 2026-17.6%
  8. 31 Dec 2025+25.5%
  9. 10 Dec 2025+11.4%

    Nothing announced by VNDA that day or the session before.

  10. 8 Dec 2025+13.9%

Share of unusual movement by asset

For each asset, the share of VNDA's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
tradipitant
events and moves
1417%
tasimelteon (Hetlioz)
events and moves
83%
Milsaperidone (VHX-896)
events and moves
4shown from 8 days
Imsidolimab
events and moves
2shown from 8 days
Assets with fewer than 8 event days, together—22%
Other company news (earnings, financing, releases naming no asset)—24%
Sessions with no dated event—33%

Assets

(6 total)
6Total Assets
4Approved
2Phase 3 / Filed
0Phase 1–2 / Early
8Diseases
Quick filter:
Showing 6 of 6 assets
Target & Modality
Approved
Dopamine D2 and serotonin 5-HT2A receptors (antagonist)Small molecule
SchizophreniaBipolar Disorder
Approved
Dopamine D2 and serotonin 5-HT2A receptors (antagonist)Small molecule
Major Depressive DisorderSchizophreniaBipolar Disorder
Approved
S1P receptorSmall molecule
Inflammatory Bowel DiseasePsoriasisMultiple Sclerosis
Ulcerative Colitis
tasimelteon(Hetlioz)
Approved
Melatonin receptor (MT1/MT2)Small molecule
Non-24-Hour Sleep-Wake Disorder
Phase 3
IL-36 receptorMonoclonal antibody
Psoriasis
Phase 3
Neurokinin-1 (NK1) receptorSmall molecule
Gastroparesis

Upcoming events

(7 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
tradipitantPhase 3Nausea and Vomiting, Obesity
Est. primary completion 2026-12-01 · NCT07446439 · CT.gov ↗
What to watch
2027 (3)
September 2027 (1)
tradipitantPhase 3Motion Sickness
Est. primary completion 2027-09-30 · NCT06138613 · CT.gov ↗
What to watch
November 2027 (2)
Iloperidone (Fanapt)Phase 3Schizophrenia
Est. primary completion 2027-11 · NCT06961968 · CT.gov ↗
What to watch
tasimelteon · HetliozPhase 3Insomnia Disorder
Est. primary completion 2027-11 · NCT06953869 · CT.gov ↗
What to watch
2028 (2)
March 2028 (1)
Milsaperidone (VHX-896)Phase 3Major Depressive Disorder (MDD)
Est. primary completion 2028-03 · NCT06830044 · CT.gov ↗
What to watch
August 2028 (1)
PonesimodPhase 3Moderate-to-severe Chronic Plaque Psoriasis
Est. primary completion 2028-08 · NCT07362017 · CT.gov ↗
What to watch
2029 (1)
April 2029 (1)
PonesimodPhase 3Ulcerative Colitis (UC)
Est. primary completion 2029-04 · NCT07686081 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(19)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Coming up

12 December 2026FDA action dateimsidolimabImsidolimab BLA PDUFA target action date
US, FDA · Vanda Pharmaceuticals · Source ↗

Recent

27 October 2026Topline resulttradipitantPhase III Study 3601 topline results in GLP-1-induced vomiting
October 2026Topline resultAQW051Phase III of VQW-765 in social anxiety disorder did not meet its primary endpoint
29 September 2026Topline resulttasimelteonPhase III study in DSWPD met its primary endpoint
Vanda Pharmaceuticals Inc. · Source ↗
3 June 2026Complete response lettertasimelteonFDA grants Vanda hearing request on proposal to refuse approval of HETLIOZ sNDA
US, FDA · FDA · Source ↗
26 March 2026Complete response lettertradipitantFDA denies hearing request and refuses to approve NDA 218489 for gastroparesis
US, FDA · FDA · Source ↗
25 February 2026Filing acceptedimsidolimabFDA accepts imsidolimab BLA
US, FDA · Vanda Pharmaceuticals · Source ↗
21 February 2026FDA action dateMilsaperidone (VHX-896)PDUFA target date set for Bysanti
US, FDA · Source ↗
20 February 2026ApprovalMilsaperidone (VHX-896)FDA approves BYSANTI (milsaperidone) for bipolar I disorder and schizophrenia
US, FDA · Source ↗
20 February 2026ApprovalMilsaperidone (VHX-896)FDA Boxed Warning on Milsaperidone (VHX-896) (NDA220358)
US, FDA · FDA · Source ↗
7 January 2026Complete response lettertasimelteonFDA says HETLIOZ jet lag sNDA cannot be approved
US, FDA · Source ↗
30 December 2025ApprovaltradipitantFDA approves NEREUS (tradipitant) for motion-induced vomiting
US, FDA · Source ↗
30 December 2025FDA action datetradipitantFDA PDUFA target date for tradipitant in motion sickness
US, FDA · Source ↗

The 12 most recent of 18 past events are shown.

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$70M$28M$62M+ $79M short-term inv.$23M-$28M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$51M$37M$56M+ $114M short-term inv.$63M-$31M operating cash flowreport ↗
2026-Q1$52M$28M$202M$49Mreport ↗
2025-Q3$56M$23M$70M+ $224M short-term inv.$23M-$32M operating cash flowreport ↗
2025-Q2$53M$22M$81M+ $245M short-term inv.$27M-$15M operating cash flowreport ↗
2025-Q1$50M$36M$112M+ $229M short-term inv.$29M-$33M operating cash flowreport ↗
2024-Q3$48M$17M$101M+ $276M short-term inv.$5.3M-$15M operating cash flowreport ↗
2024-Q2$50M$17M$103M+ $285M short-term inv.$4.5M-$6.9M operating cash flowreport ↗
2024-Q1$47M$21M$126M+ $269M short-term inv.$4.2M$7.6M operating cash flowreport ↗
2023-Q3$39M$17M$184M+ $307M short-term inv.—-$2.0M operating cash flowreport ↗
2023-Q2$46M$17M$151M+ $339M short-term inv.—-$13M operating cash flowreport ↗
2023-Q1$63M$19M$355M+ $147M short-term inv.—$32M operating cash flowreport ↗
2022-Q3$65M$25M$50M+ $405M short-term inv.—$13M operating cash flowreport ↗
2022-Q2$64M$21M$59M+ $383M short-term inv.—$5.7M operating cash flowreport ↗
2022-Q1$60M$21M$67M+ $368M short-term inv.$6.4M$4.0M operating cash flowreport ↗
2021-Q3$70M$20M$51M+ $355M short-term inv.—$9.4M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$216M$109M$85M+ $179M short-term inv.$55M-$109M operating cash flowreport ↗

Vanda reported FY2025 revenue of $216.11M, up 8.7% YoY from $198.77M, with R&D spend of $109.27M, up 46.8% YoY. Cash and equivalents were $85.32M, and the company reported a net loss of $220.47M, with quarterly net burn of $220.47M.

During the year, NEREUS (tradipitant) was approved in the U.S. for prevention of vomiting induced by motion; the Bysanti (milsaperidone) NDA for bipolar I disorder and schizophrenia was accepted with a PDUFA date of February 21, 2026. The company also highlighted ongoing Phase III programs for Fanapt long-acting injectable, Bysanti in major depressive disorder, and HETLIOZ in delayed sleep phase disorder, along with development of imsidolimab and other pipeline assets. In October 2025, Vanda entered a collaborative framework with the FDA regarding certain HETLIOZ and NEREUS disputes, and in January 2026 the FDA indicated the HETLIOZ jet lag sNDA could not be approved in its current form.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$199M$74M$103M+ $272M short-term inv.$4.7M-$16M operating cash flowreport ↗
2023-FY$193M$77M$136M+ $252M short-term inv.—$13M operating cash flowreport ↗
2022-FY$254M$86M$136M+ $332M short-term inv.—$32M operating cash flowreport ↗
2021-FY$269M$75M$53M+ $381M short-term inv.—$64M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 3 purchases ($38K), 6 sales ($2.8M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-05Duncan Charles Cliff · directorOpen-market purchase5,803$3.80$22KForm 4
2026-11-04Duncan Charles Cliff · directorOpen-market purchase3,447$3.82$13KForm 4
2026-11-03Duncan Charles Cliff · directorOpen-market purchase750$3.80$3KForm 4
2026-06-04Mitchell Stephen Ray · directorAward / grant41,600——Form 4
2026-06-04Honore Tage · directorAward / grant41,600——Form 4
2026-06-04Ward Anne Sempowski · directorAward / grant41,600——Form 4
2026-06-04DUGAN RICHARD W · directorAward / grant41,600——Form 4
2026-06-04Duncan Charles Cliff · directorAward / grant41,600——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 169 reporting institutions held 46.2M shares ($295.5M, 76.4% of shares outstanding).

#InstitutionSharesValue
1BlackRock, Inc.7,275,988$50.3M
2RENAISSANCE TECHNOLOGIES LLC3,759,559$26.0M
3STATE STREET CORP3,015,562$20.8M
4AIGH Capital Management LLC2,750,000$19.0M
5VANGUARD CAPITAL MANAGEMENT LLC2,481,491$17.1M
6MILLENNIUM MANAGEMENT LLC1,881,001$13.0M
7DIMENSIONAL FUND ADVISORS LP1,771,593$12.2M
8AQR CAPITAL MANAGEMENT LLC1,603,576$11.1M
9GEODE CAPITAL MANAGEMENT, LLC1,442,965$10.0M
10TWO SIGMA INVESTMENTS, LP1,398,201$9.7M
11JACOBS LEVY EQUITY MANAGEMENT, INC1,168,681$8.1M
12VANGUARD PORTFOLIO MANAGEMENT LLC1,014,522$7.0M
13Empire Financial Management Company, LLC922,245$6.4M
14GOLDMAN SACHS GROUP INC838,233$5.8M
15CITADEL ADVISORS LLC633,354$4.4M